“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” – 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) Post author: Post published:July 18, 2026 Post category: Continue Reading“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” – 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS)
The 7th Annual California ALS research network and PAC10 meeting Post author: Post published:July 18, 2026 Post category: Continue ReadingThe 7th Annual California ALS research network and PAC10 meeting
HD-CARE INAUGURAL SYMPOSIUM Post author: Post published:July 18, 2026 Post category: Continue ReadingHD-CARE INAUGURAL SYMPOSIUM
California ALS Research Summit 2016 Post author: Post published:July 18, 2026 Post category: Continue ReadingCalifornia ALS Research Summit 2016
Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) Post author: Post published:July 18, 2026 Post category: Continue ReadingPhase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)
A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis Post author: Post published:July 18, 2026 Post category: Continue ReadingA Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis
A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease Post author: Post published:July 18, 2026 Post category: Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease
Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome Post author: Post published:July 18, 2026 Post category: Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published:July 18, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published:July 18, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy
